-
Je něco špatně v tomto záznamu ?
Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation: Secondary Analysis of the NAVIGATE ESUS Randomized Clinical Trial
JS. Healey, DJ. Gladstone, B. Swaminathan, J. Eckstein, H. Mundl, AE. Epstein, KG. Haeusler, R. Mikulik, SE. Kasner, D. Toni, A. Arauz, G. Ntaios, GJ. Hankey, K. Perera, J. Pagola, A. Shuaib, H. Lutsep, X. Yang, S. Uchiyama, M. Endres, SB....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu srovnávací studie, časopisecké články, randomizované kontrolované studie, práce podpořená grantem
- MeSH
- Aspirin terapeutické užití MeSH
- cévní mozková příhoda farmakoterapie MeSH
- fibrilace síní MeSH
- inhibitory agregace trombocytů terapeutické užití MeSH
- inhibitory faktoru Xa terapeutické užití MeSH
- intrakraniální embolie farmakoterapie MeSH
- lidé středního věku MeSH
- lidé MeSH
- recidiva MeSH
- rivaroxaban terapeutické užití MeSH
- rizikové faktory MeSH
- sekundární prevence MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
- srovnávací studie MeSH
Importance: The NAVIGATE ESUS randomized clinical trial found that 15 mg of rivaroxaban per day does not reduce stroke compared with aspirin in patients with embolic stroke of undetermined source (ESUS); however, it substantially reduces stroke risk in patients with atrial fibrillation (AF). Objective: To analyze whether rivaroxaban is associated with a reduction of recurrent stroke among patients with ESUS who have an increased risk of AF. Design, Setting, and Participants: Participants were stratified by predictors of AF, including left atrial diameter, frequency of premature atrial contractions, and HAVOC score, a validated scheme using clinical features. Treatment interactions with these predictors were assessed. Participants were enrolled between December 2014 and September 2017, and analysis began March 2018. Intervention: Rivaroxaban treatment vs aspirin. Main Outcomes and Measures: Risk of ischemic stroke. Results: Among 7112 patients with a mean (SD) age of 67 (9.8) years, the mean (SD) HAVOC score was 2.6 (1.8), the mean (SD) left atrial diameter was 3.8 (1.4) cm (n = 4022), and the median (interquartile range) daily frequency of premature atrial contractions was 48 (13-222). Detection of AF during follow-up increased for each tertile of HAVOC score: 2.3% (score, 0-2), 3.0% (score, 3), and 5.8% (score, >3); however, neither tertiles of the HAVOC score nor premature atrial contractions frequency impacted the association of rivaroxaban with recurrent ischemic stroke (P for interaction = .67 and .96, respectively). Atrial fibrillation annual incidence increased for each tertile of left atrial diameter (2.0%, 3.6%, and 5.2%) and for each tertile of premature atrial contractions frequency (1.3%, 2.9%, and 7.0%). Among the predefined subgroup of patients with a left atrial diameter of more than 4.6 cm (9% of overall population), the risk of ischemic stroke was lower among the rivaroxaban group (1.7% per year) compared with the aspirin group (6.5% per year) (hazard ratio, 0.26; 95% CI, 0.07-0.94; P for interaction = .02). Conclusions and Relevance: The HAVOC score, left atrial diameter, and premature atrial contraction frequency predicted subsequent clinical AF. Rivaroxaban was associated with a reduced risk of recurrent stroke among patients with ESUS and moderate or severe left atrial enlargement; however, this needs to be independently confirmed before influencing clinical practice.
Bayer US LLC Pharmaceuticals Clinical Development Thrombosis Whippany New Jersey
Beijing Tiantan Hospital Capital Medical University Beijing China
Department of Human Neurosciences Sapienza University of Rome Rome Italy
Department of Internal Medicine University Hospital Basel Basel Switzerland
Department of Medicine University of Alberta Edmonton Alberta Canada
Department of Medicine University of Thesally Larissa Greece
Department of Neurology Institute of Psychiatry and Neurology Warsaw Poland
Department of Neurology OHSU VA Portland Health Care System Portland Oregon
Department of Neurology Universitätsklinikum Würzburg Würzburg Germany
Department of Neurology University of Pennsylvania Philadelphia
Instituto Nacional de Neurologia y Neurocirugia Mexico D F Mexico City Mexico
International University of Health and Welfare Sanno Hospital and Sanno Medical Center Tokyo Japan
Klinik für Neurologie Charité Universitätsmedizin Berlin Berlin Germany
Neurology Department Centro Hospitalar e Universitário de Coimbra Coimbra Portugal
Population Health Research Institute Hamilton Health Sciences Hamilton Ontario Canada
Unitat d'Ictus Servei de Neurologia Hospital Universitari Vall d'Hebrón Barcelona Spain
UWA Medical School University of Western Australia Sir Charles Gairdner Hospital Perth Australia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20023857
- 003
- CZ-PrNML
- 005
- 20201214131444.0
- 007
- ta
- 008
- 201125s2019 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1001/jamaneurol.2019.0617 $2 doi
- 035 __
- $a (PubMed)30958508
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Healey, Jeff S $u Division of Cardiology, Hamilton Health Sciences, Population Health Research Institute, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
- 245 10
- $a Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation: Secondary Analysis of the NAVIGATE ESUS Randomized Clinical Trial / $c JS. Healey, DJ. Gladstone, B. Swaminathan, J. Eckstein, H. Mundl, AE. Epstein, KG. Haeusler, R. Mikulik, SE. Kasner, D. Toni, A. Arauz, G. Ntaios, GJ. Hankey, K. Perera, J. Pagola, A. Shuaib, H. Lutsep, X. Yang, S. Uchiyama, M. Endres, SB. Coutts, M. Karlinski, A. Czlonkowska, CA. Molina, G. Santo, SD. Berkowitz, RG. Hart, SJ. Connolly,
- 520 9_
- $a Importance: The NAVIGATE ESUS randomized clinical trial found that 15 mg of rivaroxaban per day does not reduce stroke compared with aspirin in patients with embolic stroke of undetermined source (ESUS); however, it substantially reduces stroke risk in patients with atrial fibrillation (AF). Objective: To analyze whether rivaroxaban is associated with a reduction of recurrent stroke among patients with ESUS who have an increased risk of AF. Design, Setting, and Participants: Participants were stratified by predictors of AF, including left atrial diameter, frequency of premature atrial contractions, and HAVOC score, a validated scheme using clinical features. Treatment interactions with these predictors were assessed. Participants were enrolled between December 2014 and September 2017, and analysis began March 2018. Intervention: Rivaroxaban treatment vs aspirin. Main Outcomes and Measures: Risk of ischemic stroke. Results: Among 7112 patients with a mean (SD) age of 67 (9.8) years, the mean (SD) HAVOC score was 2.6 (1.8), the mean (SD) left atrial diameter was 3.8 (1.4) cm (n = 4022), and the median (interquartile range) daily frequency of premature atrial contractions was 48 (13-222). Detection of AF during follow-up increased for each tertile of HAVOC score: 2.3% (score, 0-2), 3.0% (score, 3), and 5.8% (score, >3); however, neither tertiles of the HAVOC score nor premature atrial contractions frequency impacted the association of rivaroxaban with recurrent ischemic stroke (P for interaction = .67 and .96, respectively). Atrial fibrillation annual incidence increased for each tertile of left atrial diameter (2.0%, 3.6%, and 5.2%) and for each tertile of premature atrial contractions frequency (1.3%, 2.9%, and 7.0%). Among the predefined subgroup of patients with a left atrial diameter of more than 4.6 cm (9% of overall population), the risk of ischemic stroke was lower among the rivaroxaban group (1.7% per year) compared with the aspirin group (6.5% per year) (hazard ratio, 0.26; 95% CI, 0.07-0.94; P for interaction = .02). Conclusions and Relevance: The HAVOC score, left atrial diameter, and premature atrial contraction frequency predicted subsequent clinical AF. Rivaroxaban was associated with a reduced risk of recurrent stroke among patients with ESUS and moderate or severe left atrial enlargement; however, this needs to be independently confirmed before influencing clinical practice.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a Aspirin $x terapeutické užití $7 D001241
- 650 _2
- $a fibrilace síní $7 D001281
- 650 _2
- $a inhibitory faktoru Xa $x terapeutické užití $7 D065427
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a intrakraniální embolie $x farmakoterapie $7 D020766
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a inhibitory agregace trombocytů $x terapeutické užití $7 D010975
- 650 _2
- $a recidiva $7 D012008
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a rivaroxaban $x terapeutické užití $7 D000069552
- 650 _2
- $a sekundární prevence $7 D055502
- 650 _2
- $a cévní mozková příhoda $x farmakoterapie $7 D020521
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Gladstone, David J $u Division of Neurology and Hurvitz Brain Sciences Program, Sunnybrook Health Sciences Centre and Sunnybrook Research Institute, Toronto, Ontario, Canada. Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
- 700 1_
- $a Swaminathan, Balakumar $u Population Health Research Institute, Hamilton Health Sciences, Hamilton, Ontario, Canada.
- 700 1_
- $a Eckstein, Jens $u Department of Internal Medicine, University Hospital Basel, Basel, Switzerland.
- 700 1_
- $a Mundl, Hardi $u Bayer AG, Wuppertal, Germany.
- 700 1_
- $a Epstein, Andrew E $u Electrophysiology Section, Cardiovascular Division University of Pennsylvania, Cardiology Section, Philadelphia VA Medical Center, Philadelphia.
- 700 1_
- $a Haeusler, Karl Georg $u Department of Neurology, Universitätsklinikum Würzburg, Würzburg, Germany.
- 700 1_
- $a Mikulik, Robert $u International Clinical Research Center and Neurology Department, St. Anne's University Hospital and Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Kasner, Scott E $u Department of Neurology, University of Pennsylvania, Philadelphia.
- 700 1_
- $a Toni, Danilo $u Department of Human Neurosciences, "Sapienza" University of Rome, Rome, Italy.
- 700 1_
- $a Arauz, Antonio $u Instituto Nacional de Neurologia y Neurocirugia, Mexico D.F., Mexico City, Mexico.
- 700 1_
- $a Ntaios, George $u Department of Medicine, University of Thesally, Larissa, Greece.
- 700 1_
- $a Hankey, Graeme J $u UWA Medical School, University of Western Australia, Sir Charles Gairdner Hospital, Perth, Australia.
- 700 1_
- $a Perera, Kanjana $u McMaster University/Population Health Research Institute, Department of Medicine (Neurology), Hamilton, Ontario, Canada.
- 700 1_
- $a Pagola, Jorge $u Unitat d'Ictus, Servei de Neurologia, Hospital Universitari Vall d'Hebrón, Barcelona, Spain.
- 700 1_
- $a Shuaib, Ashfaq $u Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
- 700 1_
- $a Lutsep, Helmi $u Department of Neurology, OHSU, VA Portland Health Care System, Portland, Oregon.
- 700 1_
- $a Yang, Xiaomeng $u Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
- 700 1_
- $a Uchiyama, Shinichiro $u International University of Health and Welfare, Sanno Hospital and Sanno Medical Center, Tokyo, Japan.
- 700 1_
- $a Endres, Matthias $u Klinik für Neurologie, Charité-Universitätsmedizin Berlin, Berlin, Germany.
- 700 1_
- $a Coutts, Shelagh B $u Department of Clinical Neurosciences, Radiology, and Community Health Sciences, University of Calgary, Foothills Medical Centre, Calgary, Alberta, Canada.
- 700 1_
- $a Karlinski, Michal $u Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland.
- 700 1_
- $a Czlonkowska, Anna $u 2nd Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland. Department of Pharmacology, Medical University of Warsaw, Warsaw, Poland.
- 700 1_
- $a Molina, Carlos A $u Department of Pharmacology, Medical University of Warsaw, Warsaw, Poland. Vall d'Hebron Stroke Unit. Hospital Universitari Vall d'Hebron, Barcelona, Spain.
- 700 1_
- $a Santo, Gustavo $u Neurology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
- 700 1_
- $a Berkowitz, Scott D $u Bayer US LLC, Pharmaceuticals Clinical Development Thrombosis, Whippany, New Jersey.
- 700 1_
- $a Hart, Robert G $u Population Health Research Institute, Hamilton Health Sciences, Hamilton, Ontario, Canada.
- 700 1_
- $a Connolly, Stuart J $u Division of Cardiology, Hamilton Health Sciences, Population Health Research Institute, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
- 773 0_
- $w MED00180402 $t JAMA neurology $x 2168-6157 $g Roč. 76, č. 7 (2019), s. 764-773
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30958508 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201214131442 $b ABA008
- 999 __
- $a ok $b bmc $g 1596176 $s 1114533
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 76 $c 7 $d 764-773 $e 20190701 $i 2168-6157 $m JAMA Neurology $n JAMA Neurol $x MED00180402
- LZP __
- $a Pubmed-20201125
